Haider Ali
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Haider Ali has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
- Sachin Kumar Singh
School of Pharmaceutical Sciences Lovely Professional University Phagwara Punjab India
5 shared publications - Gaurav Gupta
Centre for Research Impact & Outcome, Chitkara College of Pharmacy, Chitkara University, Punjab, India
4 shared publications Imran Kazmi
Department of Biochemistry, Faculty of Science King Abdulaziz University Jeddah Saudi Arabia
4 shared publicationsSami I. Alzarea
Department of Pharmacology, College of Pharmacy Jouf University Sakaka Aljouf Saudi Arabia
4 shared publicationsWaleed Hassan Almalki
Department of Pharmacology, College of Pharmacy Umm Al‐Qura University Makkah Saudi Arabia
4 shared publications- Ahsas Goyal
Institute of Pharmaceutical Research, GLA University, Mathura, Uttar Pradesh, India
3 shared publications
Latest Publications
- Open Access
- 14 July 2026
- Published by Forschungsgesellschaft für Arbeitsphysiologie und Arbeitsschutz e.V. in EXCLI Journal
- Vol. 25, 1117-1123
Corrigendum "Ferroptosis and circular RNAs: new horizons in cancer therapy"
EXCLI Journal - Experimental and Clinical Sciences, International Online Journal for Advances in Sciences
- 14 July 2026
- Published by Forschungsgesellschaft für Arbeitsphysiologie und Arbeitsschutz e.V. in EXCLI Journal
- Vol. 25, 1117-1123
Open AccessCorrigendum "Ferroptosis and circular RNAs: new horizons in cancer therapy"
EXCLI Journal - Experimental and Clinical Sciences, International Online Journal for Advances in Sciences
- Open Access
- 31 January 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Ubiquitination and deubiquitination as critical modulators of NSCLC tumorigenesis and drug resistance
Ubiquitination and deubiquitination are biological mechanisms that including the addition and removal ubiquitin molecules from proteins, which are associated with NSCLC. NSCLC is the most common kind of lung cancer, and treatment resistance and cancer development are linked to these alterations. Ubiquitination incorporates proteins by a particular enzyme class, and deubiquitination removes ubiquitins. In NSCLC, this modification is detrimental to cellular function and affects tumorigenesis, apoptosis, and signaling pathways. Conversely, deubiquitination refers to the process through which the ubiquitins are removed from the proteins so that they can perform their functions properly. These processes can be considered therapeutic in some sense, as regulating both can result in an effective therapy for NSCLC. Many studies have been carried out to find potential areas where further drug research could be focused. This study examines the functions of ubiquitination and deubiquitination in NSCLC pathogenesis and resistance, focusing on their mechanisms, consequences, and therapeutic possibilities. Graphical Abstract
- 31 January 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Open AccessUbiquitination and deubiquitination as critical modulators of NSCLC tumorigenesis and drug resistance
Ubiquitination and deubiquitination are biological mechanisms that including the addition and removal ubiquitin molecules from proteins, which are associated with NSCLC. NSCLC is the most common kind of lung cancer, and treatment resistance and cancer development are linked to these alterations. Ubiquitination incorporates proteins by a particular enzyme class, and deubiquitination removes ubiquitins. In NSCLC, this modification is detrimental to cellular function and affects tumorigenesis, apoptosis, and signaling pathways. Conversely, deubiquitination refers to the process through which the ubiquitins are removed from the proteins so that they can perform their functions properly. These processes can be considered therapeutic in some sense, as regulating both can result in an effective therapy for NSCLC. Many studies have been carried out to find potential areas where further drug research could be focused. This study examines the functions of ubiquitination and deubiquitination in NSCLC pathogenesis and resistance, focusing on their mechanisms, consequences, and therapeutic possibilities. Graphical Abstract
- 31 May 2025
- Published by Elsevier in Clinica Chimica Acta
- Vol. 576, 120408
Non-coding RNA biomarkers in basal-like breast cancer
- 31 May 2025
- Published by Elsevier in Clinica Chimica Acta
- Vol. 576, 120408
Non-coding RNA biomarkers in basal-like breast cancer
- Open Access
- 4 March 2025
- Published by Forschungsgesellschaft für Arbeitsphysiologie und Arbeitsschutz e.V. in EXCLI Journal
- Vol. 24, 351-380
Parthanatos and apoptosis: unraveling their roles in cancer cell death and therapy resistance
Cell death is a fundamental process that needs to be maintained to balance cellular functions and prevent disease. There are several cell death pathways; however, apoptosis and parthanatos are the most prominent and have important roles in cancer biology. As an extremely well-regulated process, apoptosis removes damaged or abnormal cells via caspase activation and mitochondrial involvement. Unlike in the healthy cells, the loss of ability to induce apoptosis in cancer permits tumor cells to survive and multiply out of control and contribute to tumor progression and therapy resistance. On the contrary, parthanatos is a caspase-independent metabolic collapse driven by poly (ADP-ribose) polymerase 1 (PARP1) overactivation, translocation of apoptosis-inducing factor (AIF), and complete DNA damage. Several cancer models are involved with parthanatos. Deoxypodophyllotoxin (DPT) induces parthanatos in glioma cells by excessive ROS generation, PARP1 upregulation, and AIF nuclear translocation. Like in acute myeloid leukemia (AML), the cannabinoid derivative WIN-55 triggers parthanatos, and the effects can be reversed by PARP inhibitors such as olaparib. Developing cancer treatment strategies involving advanced cancer treatment strategies relies on the interplay between apoptosis and parthanatos. However, such apoptosis-based cancer therapies tend to develop resistance, so there is an urgent need to look into alternative pathways like parthanatos, which may not always trigger apoptosis. In overcoming apoptosis resistance, there is evidence that combining apoptosis-inducing agents, such as BH3 mimetics, with PARP inhibitors synergistically enhances cell death. Oxidative stress modulators have been found to promote the execution of parthanatic and apoptotic pathways and allow treatment. In this review, apoptosis and parthanatos are thoroughly compared at the molecular level, and their roles in cancer pathogenesis as related to cancer therapeutic potential are discussed. We incorporate recent findings to demonstrate that not only can parthanatos be used to manage therapy resistance and enhance cancer treatment via the combination of parthanatos and apoptosis but also that immunity and bone deposition can feasibly be employed against long-circulating cancer stem cells to treat diverse forms of metastatic cancers.
- 4 March 2025
- Published by Forschungsgesellschaft für Arbeitsphysiologie und Arbeitsschutz e.V. in EXCLI Journal
- Vol. 24, 351-380
Open AccessParthanatos and apoptosis: unraveling their roles in cancer cell death and therapy resistance
Cell death is a fundamental process that needs to be maintained to balance cellular functions and prevent disease. There are several cell death pathways; however, apoptosis and parthanatos are the most prominent and have important roles in cancer biology. As an extremely well-regulated process, apoptosis removes damaged or abnormal cells via caspase activation and mitochondrial involvement. Unlike in the healthy cells, the loss of ability to induce apoptosis in cancer permits tumor cells to survive and multiply out of control and contribute to tumor progression and therapy resistance. On the contrary, parthanatos is a caspase-independent metabolic collapse driven by poly (ADP-ribose) polymerase 1 (PARP1) overactivation, translocation of apoptosis-inducing factor (AIF), and complete DNA damage. Several cancer models are involved with parthanatos. Deoxypodophyllotoxin (DPT) induces parthanatos in glioma cells by excessive ROS generation, PARP1 upregulation, and AIF nuclear translocation. Like in acute myeloid leukemia (AML), the cannabinoid derivative WIN-55 triggers parthanatos, and the effects can be reversed by PARP inhibitors such as olaparib. Developing cancer treatment strategies involving advanced cancer treatment strategies relies on the interplay between apoptosis and parthanatos. However, such apoptosis-based cancer therapies tend to develop resistance, so there is an urgent need to look into alternative pathways like parthanatos, which may not always trigger apoptosis. In overcoming apoptosis resistance, there is evidence that combining apoptosis-inducing agents, such as BH3 mimetics, with PARP inhibitors synergistically enhances cell death. Oxidative stress modulators have been found to promote the execution of parthanatic and apoptotic pathways and allow treatment. In this review, apoptosis and parthanatos are thoroughly compared at the molecular level, and their roles in cancer pathogenesis as related to cancer therapeutic potential are discussed. We incorporate recent findings to demonstrate that not only can parthanatos be used to manage therapy resistance and enhance cancer treatment via the combination of parthanatos and apoptosis but also that immunity and bone deposition can feasibly be employed against long-circulating cancer stem cells to treat diverse forms of metastatic cancers.
- 18 December 2024
- Published by Elsevier in Clinica Chimica Acta
- Vol. 567, 120105
Liquid biopsies and exosomal ncRNA: Transforming pancreatic cancer diagnostics and therapeutics
- 18 December 2024
- Published by Elsevier in Clinica Chimica Acta
- Vol. 567, 120105
Liquid biopsies and exosomal ncRNA: Transforming pancreatic cancer diagnostics and therapeutics
- 2 December 2024
- Published by Wiley in Journal of Biochemical and Molecular Toxicology
- Vol. 38 (12) , e70076
ANRIL's Epigenetic Regulation and Its Implications for Cardiovascular Disorders
Cardiovascular disorders (CVDs) are a major global health concern, but their underlying molecular mechanisms are not fully understood. Recent research highlights the role of long noncoding RNAs (lncRNAs), particularly ANRIL, in cardiovascular development and disease. ANRIL, located in the human genome's 9p21 region, significantly regulates cardiovascular pathogenesis. It controls nearby tumor suppressor genes CDKN2A/B through epigenetic pathways, influencing cell growth and senescence. ANRIL interacts with epigenetic modifiers, leading to altered histone modifications and gene expression changes. It also acts as a transcriptional regulator, impacting key genes in CVD development. ANRIL's involvement in cardiovascular epigenetic regulation suggests potential therapeutic strategies. Manipulating ANRIL and its associated epigenetic modifiers could offer new approaches to managing CVDs and preventing their progression. Dysregulation of ANRIL has been linked to various cardiovascular conditions, including coronary artery disease, atherosclerosis, ischemic stroke, and myocardial infarction. This abstract provides insights from recent research, emphasizing ANRIL's significance in the epigenetic landscape of cardiovascular disorders. By shedding light on ANRIL's role in cellular processes and disease development, the abstract highlights its potential as a therapeutic target for addressing CVDs.
- 2 December 2024
- Published by Wiley in Journal of Biochemical and Molecular Toxicology
- Vol. 38 (12) , e70076
ANRIL's Epigenetic Regulation and Its Implications for Cardiovascular Disorders
Cardiovascular disorders (CVDs) are a major global health concern, but their underlying molecular mechanisms are not fully understood. Recent research highlights the role of long noncoding RNAs (lncRNAs), particularly ANRIL, in cardiovascular development and disease. ANRIL, located in the human genome's 9p21 region, significantly regulates cardiovascular pathogenesis. It controls nearby tumor suppressor genes CDKN2A/B through epigenetic pathways, influencing cell growth and senescence. ANRIL interacts with epigenetic modifiers, leading to altered histone modifications and gene expression changes. It also acts as a transcriptional regulator, impacting key genes in CVD development. ANRIL's involvement in cardiovascular epigenetic regulation suggests potential therapeutic strategies. Manipulating ANRIL and its associated epigenetic modifiers could offer new approaches to managing CVDs and preventing their progression. Dysregulation of ANRIL has been linked to various cardiovascular conditions, including coronary artery disease, atherosclerosis, ischemic stroke, and myocardial infarction. This abstract provides insights from recent research, emphasizing ANRIL's significance in the epigenetic landscape of cardiovascular disorders. By shedding light on ANRIL's role in cellular processes and disease development, the abstract highlights its potential as a therapeutic target for addressing CVDs.
- 7 November 2024
- Published by Elsevier in Ageing Research Reviews
- Vol. 102, 102576
Epithelial–mesenchymal transition to mitigate age-related progression in lung cancer
- 7 November 2024
- Published by Elsevier in Ageing Research Reviews
- Vol. 102, 102576
Epithelial–mesenchymal transition to mitigate age-related progression in lung cancer
- 4 November 2024
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 104 (5) , e70009
CRBN‐PROTACs in Cancer Therapy: From Mechanistic Insights to Clinical Applications
Cereblon (CRBN), a member of the E3 ubiquitin ligase complex, has gained significant attention as a therapeutic target in cancer. CRBN regulates the degradation of various proteins in cancer progression, including transcription factors and signaling molecules. PROTACs (proteolysis‐targeting chimeras) are a novel approach that uses the cell's degradation system to remove disease‐causing proteins selectively. CRBN‐dependent PROTACs work by tagging harmful proteins for destruction through the ubiquitin–proteasome system. This strategy offers several advantages over traditional protein inhibition methods, including the potential to overcome drug resistance. Recent progress in developing CRBN‐based PROTACs has shown promising preclinical results in both hematologic malignancies and solid tumors. Additionally, CRBN‐based PROTACs have enhanced our understanding of CRBN's role in cancer, potentially serving as biomarkers for patient stratification and predicting therapeutic responses. In this review, we delineate the mechanisms of action for CRBN‐dependent PROTACs (CRBN‐PROTACs), summarize recent advances in preclinical and clinical applications, and provide our perspective on future development.
- 4 November 2024
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 104 (5) , e70009
CRBN‐PROTACs in Cancer Therapy: From Mechanistic Insights to Clinical Applications
Cereblon (CRBN), a member of the E3 ubiquitin ligase complex, has gained significant attention as a therapeutic target in cancer. CRBN regulates the degradation of various proteins in cancer progression, including transcription factors and signaling molecules. PROTACs (proteolysis‐targeting chimeras) are a novel approach that uses the cell's degradation system to remove disease‐causing proteins selectively. CRBN‐dependent PROTACs work by tagging harmful proteins for destruction through the ubiquitin–proteasome system. This strategy offers several advantages over traditional protein inhibition methods, including the potential to overcome drug resistance. Recent progress in developing CRBN‐based PROTACs has shown promising preclinical results in both hematologic malignancies and solid tumors. Additionally, CRBN‐based PROTACs have enhanced our understanding of CRBN's role in cancer, potentially serving as biomarkers for patient stratification and predicting therapeutic responses. In this review, we delineate the mechanisms of action for CRBN‐dependent PROTACs (CRBN‐PROTACs), summarize recent advances in preclinical and clinical applications, and provide our perspective on future development.
- 15 June 2024
- Published by Elsevier in Brain Research
- Vol. 1841, 149089
Exploring ncRNAs in epilepsy: From oxidative stress regulation to therapy
- 15 June 2024
- Published by Elsevier in Brain Research
- Vol. 1841, 149089
Exploring ncRNAs in epilepsy: From oxidative stress regulation to therapy
- Open Access
- 25 April 2024
- Published by Forschungsgesellschaft für Arbeitsphysiologie und Arbeitsschutz e.V. in EXCLI Journal
- Vol. 23, 570-599
Ferroptosis and circular RNAs
Cancer poses intricate challenges to treatment due to its complexity and diversity. Ferroptosis and circular RNAs (circRNAs) are emerging as innovative therapeutic avenues amid the evolving landscape of cancer therapy. Extensive investigations into circRNAs reveal their diverse roles, ranging from molecular regulators to pivotal influencers of ferroptosis in cancer cell lines. The results underscore the significance of circRNAs in modulating molecular pathways that impact crucial aspects of cancer development, including cell survival, proliferation, and metastasis. A detailed analysis delineates these pathways, shedding light on the molecular mechanisms through which circRNAs influence ferroptosis. Building upon recent experimental findings, the study evaluates the therapeutic potential of targeting circRNAs to induce ferroptosis. By identifying specific circRNAs associated with the etiology of cancer, this analysis paves the way for the development of targeted therapeutics that exploit vulnerabilities in cancer cells. This review consolidates the existing understanding of ferroptosis and circRNAs, emphasizing their role in cancer therapy and providing impetus for ongoing research in this dynamic field.
- 25 April 2024
- Published by Forschungsgesellschaft für Arbeitsphysiologie und Arbeitsschutz e.V. in EXCLI Journal
- Vol. 23, 570-599
Open AccessFerroptosis and circular RNAs
Cancer poses intricate challenges to treatment due to its complexity and diversity. Ferroptosis and circular RNAs (circRNAs) are emerging as innovative therapeutic avenues amid the evolving landscape of cancer therapy. Extensive investigations into circRNAs reveal their diverse roles, ranging from molecular regulators to pivotal influencers of ferroptosis in cancer cell lines. The results underscore the significance of circRNAs in modulating molecular pathways that impact crucial aspects of cancer development, including cell survival, proliferation, and metastasis. A detailed analysis delineates these pathways, shedding light on the molecular mechanisms through which circRNAs influence ferroptosis. Building upon recent experimental findings, the study evaluates the therapeutic potential of targeting circRNAs to induce ferroptosis. By identifying specific circRNAs associated with the etiology of cancer, this analysis paves the way for the development of targeted therapeutics that exploit vulnerabilities in cancer cells. This review consolidates the existing understanding of ferroptosis and circRNAs, emphasizing their role in cancer therapy and providing impetus for ongoing research in this dynamic field.